ArticleCancer reports (Hoboken, N.J.)2026

A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi-Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De-Differentiated Chondrosarcoma.

Matthew Youssef et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.